KRAS and lung adenocarcinoma: In addition to EGFR mutations and ALK rearrangements, genomic studies have also identified frequent copy number changes and somatic mutations affecting components of key signaling pathways in adenocarcinoma of the lung including KRAS, Her2, BRAF, C-MET, MEK1 and PIK3CA [24,25] (Table 1).